



---

*Correction*

---

**Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and *In Vitro* Evaluation**

Emine Tashan,<sup>1,2</sup> Alptug Karakucuk,<sup>1</sup> and Nevin Celebi<sup>1,3</sup>

**Correction to: AAPS PharmSciTech 21, 115 (2020)**

<https://doi.org/10.1208/s12249-020-01653-9>

Several typos occurred during the production process and captions were misplaced. The corrected captions for Picture 1, Fig. 6, Fig. 7, Fig. 8 and Fig. 9 are below.

---


The online version of the original article can be found at <https://doi.org/10.1208/s12249-020-01653-9>

---


<sup>1</sup>Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey.

<sup>2</sup>Zoleant Pharmaceuticals International, Istanbul, Turkey.


<sup>3</sup>To whom correspondence should be addressed. (e-mail: [ncelebi51@gmail.com](mailto:ncelebi51@gmail.com))




**Fig. 6.** Dissolution profiles of ODTs in pH 7.4 phosphate buffer



**Fig. 7.** Dissolution profiles of ODTs in pH 7.4 phosphate buffer + 1% SLS



**Fig. 8.** Cell viabilities (%) for the sample groups (n=6)



**Fig. 9.** Cumulative amount of ZHM in basolateral membrane



**Picture. 1.** Appearance of nanocrystal based ODTs